Lecap Asset Management Ltd. Makes New $326,000 Investment in Exelixis, Inc. (NASDAQ:EXEL)

Lecap Asset Management Ltd. purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) during the third quarter, HoldingsChannel reports. The fund purchased 12,553 shares of the biotechnology company’s stock, valued at approximately $326,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Fisher Asset Management LLC increased its holdings in shares of Exelixis by 232.6% in the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 728 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in shares of Exelixis in the 3rd quarter valued at approximately $30,000. Park Place Capital Corp bought a new stake in Exelixis during the 2nd quarter worth approximately $45,000. GAMMA Investing LLC raised its holdings in Exelixis by 107.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,041 shares during the period. Finally, EntryPoint Capital LLC lifted its stake in Exelixis by 537.2% in the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 1,746 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Ratings Changes

EXEL has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $29.00 price objective on shares of Exelixis in a research report on Wednesday, September 18th. The Goldman Sachs Group upgraded Exelixis to a “strong sell” rating in a report on Tuesday, October 15th. Stifel Nicolaus boosted their price target on Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a report on Wednesday, October 16th. Royal Bank of Canada upped their price objective on Exelixis from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Finally, StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. One analyst has rated the stock with a sell rating, five have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.57.

Exelixis Trading Down 0.7 %

NASDAQ EXEL opened at $28.11 on Friday. The firm has a market capitalization of $8.52 billion, a P/E ratio of 43.92, a price-to-earnings-growth ratio of 0.54 and a beta of 0.54. The firm’s fifty day moving average price is $26.58 and its two-hundred day moving average price is $23.97. Exelixis, Inc. has a 1 year low of $19.12 and a 1 year high of $29.75.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The company had revenue of $637.18 million for the quarter, compared to analysts’ expectations of $468.21 million. On average, research analysts anticipate that Exelixis, Inc. will post 1.59 EPS for the current fiscal year.

Insider Buying and Selling at Exelixis

In other news, CFO Christopher J. Senner sold 125,000 shares of Exelixis stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the completion of the transaction, the chief financial officer now directly owns 721,680 shares in the company, valued at approximately $19,622,479.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, EVP Dana Aftab sold 95,000 shares of Exelixis stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the completion of the sale, the executive vice president now owns 520,990 shares of the company’s stock, valued at approximately $13,024,750. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Christopher J. Senner sold 125,000 shares of Exelixis stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the completion of the sale, the chief financial officer now owns 721,680 shares of the company’s stock, valued at $19,622,479.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 327,858 shares of company stock worth $8,640,129 over the last 90 days. Company insiders own 2.85% of the company’s stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.